On December 19th, 222, Yiling Pharmaceutical Co., Ltd. fell sharply from the opening, and finally closed at the limit. Subsequently, the corresponding concept stocks of COVID-19 Pharmaceuticals plummeted. Today, the overall market plummeted, and the Shanghai Stock Exchange fell by -1.92%. Interestingly, the pharmaceutical stocks in COVID-19 rose the most recently, and the real estate concept stocks fell the most.

why did you stop at Yiling? Mainly due to a rumor. It is rumored that Lianhua Qingwen can cause liver injury and liver failure, which will do great harm to the body. Subsequently, the company urgently issued a "Statement on the Safety of Lianhua Qingwen".

In fact, if you look at it normally, it's nothing, but shareholders can't take it anymore? Since September, the number of epidemic cases has surged, especially after the release of cold and fever drugs; As a result, Yiling Pharmaceutical rose from 18 yuan to 53 yuan, which once increased nearly 3 times! ! Now it has formed a monster stock, which attracts many speculators who chase it in from a high position.

First, everyone knows that it is expensive. Second, they don't know the company clearly. The value of the third equity has accumulated a lot of profit chips, so investors are still very anxious. At this time, Yiling's share price is often very sensitive. Once there is bad news, whether it is true or not, after timely clarification, it is bound to be a plunge.

The supply of drugs in Beijing has started to rise. In addition, most people have started to work one after another after a week. In the future, the shortage of drugs will not last long, and it will return to calm. Now, I think the fever of COVID-19 pharmaceutical stocks will drop in the future. We suggest staying away, so we should invest rationally and not blindly.

Actually, I started to be cautious half a month ago. Why? The reason is not complicated, it has gone up a lot.

The Central Economic Work Conference was held at the weekend, and many people gave high expectations. In fact, if you look closely, it is still a cliche to develop the economy and domestic demand. Stock speculation is expected, and sometimes it really comes to this day, which is often a big drop. Just like this summer's new energy performance announcement period, many of the performance doubled, and the result was a sharp drop on the same day. Therefore, in today's market, I think it is still rising much, and there is a demand for profitable chips to be cashed.

Today, the decline is really scary. In fact, if you look closely, it is mainly concentrated in the real estate and medicine sectors, which have risen too high during this period. These two sectors are also the main force of the recent market rise, and they are basically the realization of short-term profit chips. Most stocks did not fall deeply.

I suggest that in the short and medium term, you can wait for the risk to be released, which may be more difficult. If you don't invest enough, you need to concentrate.

Yiling Pharmaceutical was established in 1992, and listed on the A-share market in July 211. Its main business is the research and development, production and sales of patented innovative traditional Chinese medicines, among which Lianhua Qingwen series capsules/granules have attracted attention due to their multiple visits to COVID-19.

According to the company, Lianhua Qingwen series capsules/granules are the first patented new drugs that apply collateral disease theory to explore the pathogenesis and treatment of exogenous febrile diseases and guide research and development, which can effectively inhibit bacteria, regulate immunity, resist inflammation and reduce fever, relieve cough and resolve phlegm. In April, 22, National Medical Products Administration approved Lianhua Qingwen Capsule/Granule to add a new indication of "novel coronavirus light and ordinary type" on the basis of the original approved indication.

At present, Yiling Pharmaceutical has not directly disclosed the performance of Lianhua Qingwen. However, in the record of investor relations activities made public on October 28, Yiling Pharmaceutical mentioned that the sales revenue of the company's formula granule business increased well year-on-year in the first three quarters of 222. In a suggestive announcement on March 17 this year, Yiling Pharmaceutical mentioned that in the first three quarters of 221, the company realized an operating income of 3.37 billion yuan from Lianhua Qingwen products, accounting for 41.6% of the company's total operating income.